X

Trial Profile

Investigation of the Safety and Efficacy of Semaglutide s.c. in Combination With NNC0480-0389 in Participants With Type 2 Diabetes - a Dose Finding Study

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Apr 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NNC0480-0389 (Primary) ; Semaglutide (Primary)
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Sponsors Novo Nordisk

Most Recent Events

11 Apr 2024 This trial has been completed in Greece (End date:2023-03-23) according to European Clinical Trials Database record.
30 Mar 2023 Status changed from active, no longer recruiting to completed.
11 Nov 2022 Planned End Date changed from 30 Jan 2023 to 20 Mar 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com